Alembic Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Updated: 20 Mar 2026 • 5:35 pm
Posted by:
Alembic Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Alembic was listed on the National Stock Exchange (NSE) on 22-Sep-1999. Alembic share has its face value of 2 per share, and its NSE symbol is ALEMBICLTD. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Alembic Q4 Results 2026 Preview
- Alembic Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 16-22% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 18-25% YoY.
- EBITDA to rise 17-23%.
- Alembic is expected to show Strong Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Alembic Share Performance
- Over the past six months, Alembic share price has Up by 30% to 79.67.
- Moreover, over the past year, the stock has Up by 52%
- Despite this weak short-term performance, Alembic stock has delivered a financially sound 260% return over the past 5 years.
- As of today, 20-03-2026, the Alembic share price is trading at 79.67 per share.
Key Factors to Watch for Alembic Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Alembic
Alembic is a pharmaceutical company engaged in the manufacturing and marketing of generic formulations and active pharmaceutical ingredients, serving both domestic and international markets. It is known for a diversified product portfolio and a strong focus on research and development.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Alembic is gear up to announce its Q4 FY26 results. Analysts expect 16-22% revenue growth, a 18-25% rise in PAT, and a 17-23% rise in EBITDA. Alembic focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Alembic Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Siemens Energy Q4 FY26 Earnings Preview Expectations Outlook
Entertainment Network Q4 FY26 Earnings Preview Outlook
Energy Development Q4 FY26 Earnings Preview Outlook
Endurance Technologies Q4 FY26 Earnings Preview Expectations Outlook
Recent Articles
Sobha Target Price Rs 1,900: Why Emkay Stays Positive Despite an 18% YTD Fall, With 59% Upside, a Rs 1,571 NAV, SOTP Valuation, the Q2 Business Update and the Risks
5 October 2026
Sobha Target Price Rs 1,900: Why Emkay Stays Positive Despite an 18% YTD Fall, With 59% Upside, a Rs 1,571 NAV, SOTP Valuation, the Q2 Business Update and the Risks
5 October 2026
Jio IPO Buzz: Latest After the US, UK and Dubai Roadshows by Akash and Isha Ambani, the Rs 37,000 to 37,800 Crore Issue, Valuation Estimates and the Financials Investors Are Reading
5 October 2026
Jio Platforms IPO Date: Opening on 21 October, Listing on 28 October, the $3.8 Billion Issue Size, Timeline, How to Apply and What Is Still Unconfirmed
5 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sobha Target Price Rs 1,900: Why Emkay Stays Positive Despite an 18% YTD Fall, With 59% Upside, a Rs 1,571 NAV, SOTP Valuation, the Q2 Business Update and the Risks
Sobha Target Price Rs 1,900: Why Emkay Stays Positive Despite an 18% YTD Fall, With 59% Upside, a Rs 1,571 NAV, SOTP Valuation, the Q2 Business Update and the Risks
Jio IPO Buzz: Latest After the US, UK and Dubai Roadshows by Akash and Isha Ambani, the Rs 37,000 to 37,800 Crore Issue, Valuation Estimates and the Financials Investors Are Reading
Jio Platforms IPO Date: Opening on 21 October, Listing on 28 October, the $3.8 Billion Issue Size, Timeline, How to Apply and What Is Still Unconfirmed
SEBI Closing Auction Rules: Why the Regulator May Partly Reverse Them After Sharp Derivatives Price Swings, What Changes for Expiry-Day Settlement and What Traders Should Watch
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times